Aligos Therapeutics
ALGS
71 hedge funds and large institutions have $390M invested in Aligos Therapeutics in 2021 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 23 increasing their positions, 16 reducing their positions, and 8 closing their positions.
44% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 16
38% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 8
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
4% more funds holding
Funds holding: 68 → 71 (+3)
0.16% more ownership
Funds ownership: 2.93% → 3.09% (+0.16%)
19% less capital invested
Capital invested by funds: $484M → $390M (-$93.6M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LGM
Logos Global Management
San Francisco,
California
|
+$16.8M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$16.5M |
| 3 |
BlackRock
New York
|
+$5.23M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.45M |
| 5 |
EC
EcoR1 Capital
San Francisco,
California
|
+$1.33M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$6.09M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$3.9M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$3.87M |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$2.13M |
| 5 |
Norges Bank
Oslo,
Norway
|
-$1.59M |
ALGS Hedge Fund Activity: Q4 2021 in Review
71 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Aligos Therapeutics (ALGS) for Q4 2021, worth a combined $390M — down 19% from $484M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new ALGS positions and 8 closed out — a net gain of 3 holders — while 23 added to existing stakes and 16 trimmed.
The largest buyer was Logos Global Management, adding an estimated $16.8M. The largest seller was Morgan Stanley, cutting an estimated $6.09M.
- 71 institutional investors held Aligos Therapeutics (ALGS) as of Q4 2021, up from 68 in Q3 2021.
- Funds reported $390M of Aligos Therapeutics stock for Q4 2021, down 19% quarter-over-quarter.
- 11 funds opened new Aligos Therapeutics positions in Q4 2021 and 8 closed out, a net change of +3 holders.
- The largest Aligos Therapeutics buyer in Q4 2021 was Logos Global Management, an estimated $16.8M added.
- The largest Aligos Therapeutics seller in Q4 2021 was Morgan Stanley, an estimated $6.09M sold.
Based on aggregated 13F filings for Q4 2021.